Previous work demonstrated that the C5aR1 antagonist, PMX205, decreased amyloid pathology and suppressed cognitive deficits in two Alzheimer's Disease (AD) mouse models. The gene discussed is C5AR1; the disease is early-onset autosomal dominant Alzheimer disease.